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Background: The association between infarct artery size and clinical outcomes after
percutaneous coronary intervention has not been characterized. We hypothesized that
patients with large vessel infarction would have worse clinical outcomes.
Methods: A total of 3,274 patients enrolled in the Korea Acute Myocardial Infarction
Registry who underwent only one DES implantation for IRA were grouped according to
infarct vessel diameter: group I (small vessel, implanted DES diameter  2.75mm,
N635, male 60.3%) and group II (large vessel (implanted DES diameter 2.75mm,
N2,639, male 77.1%). Patients with multi-vessel or left-main disease were excluded.
The primary endpoint was major adverse cardiac events (MACE), including death, MI,
and target lesion revascularization at 12 months after percutaneous coronary intervention
(PCI).
Results: Patients in group I were older (62.412.4 vs. 58.612.5 years, p0.001); had
higher prevalence of diabetes (24.8 vs. 19.8%, p0.009), hypertension (45.7 vs. 38.5%,
p0.001), and stenotic lesions in the left circumflex coronary artery (28.3 vs. 11.2%,
p0.001); and were more likely to have lower level of maximal troponin-I (37.871.7 vs.
55.9112.7 ng/mL, p0.001). There were no differences between the group in Killip
classification, dyslipidemia, lesion characteristics, stent length, pre- and post-PCI Throm-
bolysis In Myocardial Infarction flow (TIMI). In-hospital mortality was higher in group
I (3.0 vs. 1.4%, p0.012). During follow-up, however, the rates of composite of MACE
at 1, 6, 12 months were not statistically between the two groups. In multivariate analysis,
Killip classII (odds ratio (OR), 8.358; 95% confidence interval (CI), 3.109  22.466;
p0.001), age65 years (OR, 4.106; 95% CI, 1.287  12.094; p0.017), pre-
procedural TIMI flow grade 0 (OR, 2.802; 95% CI, 1.021  7.693; p0.045), ejection
fraction 40% (OR, 7.042; 95% CI, 2.551  19.607; p0.001) were independent
predictors of in-hospital mortality.
Conclusions: Patients with small vessel infarction had similar angiographic and clinical
outcomes, compared to those with large vessel infarction after PCI with DES during a
12-month clinical follow-up.
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Background: The use of advanced imaging modalities for early determination of infarct
size is limited in daily practice and therefore, it would be of particular use to estimate
infarct size and prognosis by troponin (cTnT).
Methods: The value of peak and serial 6h high-sensitive (hs) cTnT for estimation of
infarct size as 48h cumulative CK release (Q48CK), LV function at 3 months as wall
motion score index (WMSI) and LV ejection fraction (LVEF), and adverse clinical
outcome as the composite of all-cause death, ICD implantation or hospitalization for heart
failure, was studied in patients who underwent primary PCI for first STEMI.
Results: In 188 consecutive patients (6112 yrs, 72% men), peak and all fixed time
hs-cTnT values were significantly correlated with Q48CK, WMSI and LVEF, of which
the value at 24h after onset of symptoms (hs-cTnT24) demonstrated the best correlation
(r0.86, 0.47 and 0.59 [p0.001], respectively). With the addition of hs-cTnT values
separately to multivariate regression models, all were independent predictors of Q48CK,
WMSI and LVEF but hs-cTnT24 was demonstrated to have the greatest impact on the
outcomes with an increase in R2 of 0.51, 0.09 and 0.18 (p0.001), respectively.
Moreover, all cTnT values independently predicted adverse clinical outcome, of which
hs-cTnT24 again showed the largest influence (HR 3.77 [95%CI 2.12-6.73], p0.001,
Figure).
Conclusions: Not only peak, but all fixed time hs-cTnT values were predictive of infarct
size, LV function 3 months and adverse clinical outcome 1 year after STEMI, particularly
24h after the onset of symptoms.
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Background: Patients (pts) presenting with STEMI to facilities that do not perform PCI
receive lytics and/or are transferred. AHA’s Mission: Lifeline “Strategies for the Ideal
STEMI-Referral Hospital” recommends Door In Door Out (DIDO) time within 30
minutes for the referring hospital (1). The Omaha Veterans Administration Medical
Center (OVAMC) transfers pts presenting with STEMI to its affiliate, The Nebraska
Medical Center (TNMC). These pts are treated/ transferred from the emergency room
(ER) of the OVAMC by staff physicians and by residents/fellows after hours. A STEMI
task force was formed at the OVAMC in the fall of 2011 to study the transfer process and
outcomes of patients from the ER to TNMC.
Methods: Multiple parameters were tracked including the (DIDO) time, initial EKG,
medications, time of day, transportation and physicians. Significant protocol changes were
put in place after the initial observation period from Dec 10, 2011 to Feb 2, 2012 (period
1). A STEMI monitoring committee was established at OVAMC. Data on DIDO was
collected from Feb 11, 2011 to May 23, 2012 (period 2). Wilcoxon rank sum test was used
to compare DIDO times between periods and p-values less than 0.05 are statistically
significant.
Results: Median DIDO times significantly decreased from period 1 to period 2 in all
groups. Staff physicians(SP)had significantly lower DIDO than resident/fellow (R/F)in
period 2 (p0.0018)(table 1). The rate of successful DIDO within 30 min improved for
all pts. SP improved from 0% to 92% (p0.033) but RF did not 12% to 25% (p1.0)
Door In Door Out (min)
Period 1 Period 2
Median
Change p-value
# Patients SP/RF 2/8 12/8
All Patients SP median
(range)
83.5 (30-161) 26.5 (15-67) 57 0.0001
Staff Physician SP
median (range)
52 (48-56) 20 (15-39) 32 0.035
Resident/Fellow RF
median (range)
84.5 (30-161) 32.5 (26-67) 52 0.0074
Conclusions: 1. Streamlining the transfer process of STEMI patients can have a
significant impact on DIDO time. 2. The level of training of the physician can have a
significant impact on DIDO performance measures. 3. Transferring facilities that accept
STEMI patients must have a streamlined DIDO protocol and E.R. level trained physicians
in order to meet guidelines.
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Background: Patients with large myocardial infarcts (MI) suffer from left ventricular
(LV) remodeling irrespective of successful revascularization; this process may be
prevented by cardiac stem cell therapy. Intracoronary application of mononuclear cells
derived from bone marrow (BMC) is safe but not sufficiently effective; trans-endokardial
application may be more effective. Here we describe the re-sults of the single-center,
prospective, controlled, open-label ALSTER-Stem Cell trial. Patients with symptomatic
heart failure following acute MI received trans-endocardial application of BMC to
improve left ventricular (LV)-function and clinical outcome.
Methods: We recruited 12 patients following acute MI with: LVEF45% measured by
cardiac MRI (CMR) and NYHA classII despite successful revascularization. A
subgroup of patients (n11) included in the previously published LIPSIAbciximab trial
also receiving serial CMR measurements was used as a matched control group. 193
days after revascularization patients were subjected to injection of BMC into the infarct
border zone employing the MYOSTAR injection catheter following electroanatomical
LV-mapping via the NOGA-XP system (Biosense Webster, Diamond Bar, USA).
Measurements of the CMR and further clinical investigations (rehospitalisation for
decompensated heart failure, 6min-walk-test, NT-proBNP-levels) were performed at
baseline and 6 months follow up.
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